How Does Cannabis Affect the Immune System?

Cannabis can influence immune signaling, but human research does not support describing it as a reliable immune booster or an established treatment for autoimmune disease. Changes in inflammation markers are not the same as fewer infections, prevention of organ damage, or better disease control. Effects depend on the cannabinoid, dose, route, and the person’s underlying health.

Immune Signaling Is Not a Simple On-Off Switch

The endocannabinoid system includes signaling molecules and receptors involved in many functions. CB2 receptors are prominent on immune cells, while CB1 receptors are especially important in the nervous system. THC and CBD have different pharmacology; their effects should not be treated as interchangeable.

Laboratory experiments have found effects on immune-cell activity and inflammatory signaling. However, the National Academies’ immunity review emphasized the limited human evidence. A finding in cultured cells or an animal model cannot determine whether a commercial cannabis product will improve immune function in a person.

What Human Studies Show

A 2025 systematic review of 40 clinical studies, including nine randomized placebo-controlled trials, found that most studies reported no change in cytokines, T-cell counts, or C-reactive protein with cannabis exposure. In some autoimmune conditions, symptoms improved while objective immune markers did not. The authors called for better prospective research.

A 2026 review of regular cannabinoid use and inflammatory biomarkers likewise complicates the idea that cannabis uniformly reduces inflammation. Its observational findings linked use with increases in both pro-inflammatory and anti-inflammatory markers. Differences in study design, population, and recent use affected the findings. Biomarker associations alone cannot establish a treatment benefit or a diagnosis of immune suppression.

The useful question is therefore specific: does a defined product improve a meaningful outcome in a particular disease? “Modulating” immunity simply means changing it; it does not necessarily mean normalizing or strengthening it.

Autoimmune Disease and Cancer Treatment

Pain relief should not be confused with slowing an autoimmune disease. For example, a 2026 systematic review in inflammatory bowel disease found mixed symptom results and no meaningful benefit for remission or endoscopic outcomes in a body of evidence at high risk of bias. Feeling better does not establish that intestinal inflammation is controlled.

The 2025 immune review also examined concerns about cancer checkpoint inhibitors. It did not find consistent changes in the immune markers studied, but that does not prove cannabis has no effect on cancer-treatment outcomes. Patients receiving immunotherapy should discuss cannabis with their oncology team rather than assuming either safety or interference based on laboratory mechanisms alone.

Do not substitute cannabis for prescribed immunosuppressants, disease-modifying treatment, cancer therapy, or antiretroviral medicines. Symptom management and control of the underlying disease require separate assessment.

Infection Exposure and Drug Interactions

Contamination is a different issue from cannabinoid effects on immunity. Cannabis can carry fungi. A CDC-authored insurance-claims study found an association between coded cannabis use and fungal infections, although infections were uncommon and the study could not identify where infection came from. It does not prove cannabis caused every infection or that all users become immunocompromised.

People receiving transplants, chemotherapy, corticosteroids, or biologic medicines can be especially vulnerable to invasive mold infections. Discuss cannabis exposure with the treating team, particularly if immune defenses are already reduced.

Medication interactions can be clinically important even when CBD causes no intoxication. In a phase I study reported in 2025, 12 healthy participants took CBD titrated to 5 mg/kg twice daily. With CBD, tacrolimus peak concentration increased 4.2-fold and overall exposure increased 3.1-fold. These results do not predict the exact effect of every CBD product, but they show why transplant patients need specialist review and drug-level monitoring. Do not adjust tacrolimus yourself.

Other Harms Should Be Described Accurately

Cannabinoid hyperemesis syndrome can cause repeated vomiting, dehydration, and electrolyte problems. It should not be described as proven progressive immune suppression causing secondary infections. Severe vomiting or inability to keep fluids down needs medical assessment.

There is no established cannabis dose or strain for “balancing” immunity. If you use cannabis, tell your clinician the product, ingredients, route, and frequency. Judge any proposed benefit by disease-specific clinical evidence and meaningful outcomes, while checking interactions and risks related to your existing treatment.